Ab&B Bio-Tech Co Ltd (Ticker: 2627 HK) is a China-based company specializing in the research, development, and commercialization of innovative vaccines. Ab&B Bio-Tech plans to list on the Hong Kong Stock Exchange on August 8, 2025, offering 33.44 million shares at a price range of HKD12.90 to HKD15.50. The company aims to raise up to HKD518.36 million (approximately USD60.5 million), which would value it at up to USD711.71 million. Proceeds will reportedly be used for the research and development of its product pipeline, including advancing its human rabies vaccine candidate into Phase III clinical trials. The company's core products include an already commercialized quadrivalent subunit influenza vaccine and the aforementioned rabies vaccine candidate.